| |
|
|
|
|
| |
 |
|
Aegera Therapeutics is a clinical stage biotechnology company focused on developing targeted therapeutics to address major unmet medical needs. Aegera has two oncology programs in clinical development. Aegera is also dedicated to identifying novel development candidates based upon its core technologies and internal expertise and experience in rapidly moving lead candidates through preclinical development and into clinical trials.
- AEG35156 targets the key anti-apoptotic protein XIAP, and is in Phase 2 clinical trials for the treatment of solid tumors and hematological malignancies;
- AEG40826 (HGS1029) is a small molecule pan-IAP inhibitor that has demonstrated very promising preclinical activity across a broad range of cancers. A collaboration and license agreement was completed in December 2007 with Human Genome Sciences, Inc. (Nasdaq:HGSI) and a Phase 1 trial initiated in Q2/08;
- Leverage our knowledge, expertise and intellectual property to bring targeted therapeutics from preclinical development to clinical proof of concept.
- Seek top-tier global and regional partners for our clinical development programs and carefully evaluate earlier stage partnerships where intellectual, research and development synergies can significantly accelerate program development.
- In-license or acquire new therapeutic candidates that can rapidly be brought to human proof-of-concept clinical testing by leveraging our proven preclinical and early clinical development expertise and targeted therapeutic focus.
|
|
| |
|
|
|
|
|
